The company’s polyether polyols primarily support the isocyanates business to complement the solutions the company offers to customers. The Coatings, Adhesives, Specialties business unit offers basic and modified isocyanates. The company has combined its activities in the area of surfaces and carrier materials in the new ‘Functional Films and Specialties’ unit. This area includes applications in cosmetics, medical technology, carbon nanotubes for improving the properties of plastics and metals, and the activities of the Functional Films unit, which include three-dimensionally formable electroluminescent films, LCD diffuser films for flat screens, formable coated films for electronic and automotive applications and Makrofol soft-touch films used in automotive interior components and cellphone housings. The service functions Procurement and Trading, Technology Services, Health Safety Environment & Quality, Corporate Energy Policy & Reporting, along with site management at the multibusiness- unit sites in Baytown and Shanghai, are combined with in the Industrial Operations unit. In addition, the Basic Chemicals unit ensures the supply of chlorine, sodium hydroxide solution, hydrogen, carbon monoxide and nitric acid at the German plants on the Lower Rhine and at the multi-business-unit sites. Sales and Marketing The company has operations in Europe, North America, the Asia Pacific, Latin America, Africa, and the Middle East. It sells its products through super market chains, drug stores, large retailers, pharmacies, and hospitals, as well as directly to patients. Significant Events Bayer AG and Germany's state of North-Rhine-Westphalia have signed a contract that stipulates that Bayer's controversial carbon monoxide (CO) pipeline project in that state is in the public interest. The 67km pipeline, which connects Bayer's sites in Dormagen and Krefeld-Uerdingen, is approximately 99% complete. On April 28, 2009, Bayer AG announced that it has signed a deal with U.S. company Ardea Biosciences Inc. to develop cancer treatments. The agreement between the Bayer HealthCare unit and San Diego-based Ardea centers on developing so-called MEK inhibitors for the treatment of solid tumors. Ardea would be responsible for completing phase I and II studies under way for the lead compound in the program, known as RDEA119. In December 2009, Utexrwa has entered into a partnership with Bayer AG to produce 70,000 anti-malaria bed nets. The project would have the capacity to produce over 12 million nets per year for local and the export markets. On March 23, 2010, the company has entered into a research collaboration and license agreement with Prometheus Laboratories Inc. The partnership would focus on the development of companion diagnostics for Bayer's pipeline of oncology drugs. History Bayer Aktiengesellschaft was founded in 1863.
(BAYZF:OTC Markets Group Inc - Current Information)
Phone: 49 214 301
|Actavis plc||$304.76 USD||+1.20|
|Bristol-Myers Squibb Co||$65.76 USD||+0.50|
|Gilead Sciences Inc||$100.69 USD||-0.31|
|Novo Nordisk A/S||kr376.80 DKK||+7.10|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BAYER AG-REG, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.